FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

l	OMB APPROVAL							
l	OMB Number:	3235-0287						
l	Estimated average burde	en						
l	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and BERNS		2. Issuer Name <b>and</b> Ticker or Trading Symbol  Jazz Pharmaceuticals plc [ JAZZ ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					ner			
(Last) C/O JAZZ CONNAU	08/0	3. Date of Earliest Transaction (Month/Day/Year) 08/08/2013									Officer below)	(give title		Other (s below)	pecify			
4		4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) DUBLIN 4 L2													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
		Table	e I - Non-Der	ivative	Sec	urities	Acc	quired, I	Dis	osed o	f, or Be	nefici	ally C	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					r) Ex	A. Deemed kecution Date, any lonth/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities Acquired (ADDisposed Of (D) (Instr. 3D)  5)						s Formally (D) (Sollowing (I) (II)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
					Code	v	Amount	(A) oi (D)	Price	rice Tran		on(s) nd 4)			Instr. 4)			
Ordinary S	hares	08/2013	/2013		A <sup>(1)</sup>		2,250 A		\$	0	4,500			D				
		Та	able II - Deriv (e.g.,							osed of, onvertib				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code (				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title ar Amount of Securitie Underlyin Derivativ (Instr. 3 a	De Se (In	Price of erivative ecurity istr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amou or Numb of Share	er					
Nonstatutory Stock Option (right to buy)	\$81.76	08/08/2013		A		4,500		(2)		08/07/2023	Ordinary Shares	4,50	0	\$0	4,500		D	

## **Explanation of Responses:**

- 1. These restricted stock units are granted pursuant to the Issuer's 2007 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2014.
- 2. This option is granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vests in 12 equal monthly installments beginning on September 1, 2013.

## Remarks:

/s/ Larissa Schwartz as attorney in fact for Paul Berns

\*\* Signature of Reporting Person

08/12/2013

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of SUZANNE SAWOCHKA HOOPER, VALERIE PIERCE, SOFIA LOU and LARISSA SCHWARTZ signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- 1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Jazz Pharmaceuticals plc (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- 2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- 3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company or any of its affiliates, assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company or an affiliate of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of February 2013.

/s/ Paul L. Berns

PAUL L. BERNS